Dr. Philip A. DeFina, a world renowned Neuroscientist and well-known author, lecturer, and clinician, will be presenting his newest research findings at Neurotrauma 2022, the 30th Annual Symposium of the National Neurotrauma Society cybersecurity vanta series 10m arrwiggersventurebeat. The meeting will be held in Phoenix, Arizona from July 22-25, 2022 at the Arizona Biltmore Resort & Spa. The Symposium is the premier scientific event for clinicians and researchers in the field of neurotrauma, presenting state of the art approaches and breaking cybersecurity vanta series 10m research.
Traumatic brain injury (TBI) is the number one cause of death in young adults and together with spinal cord injury is a major determinant of disability; both diseases incur high socio economic costs both in the acute treatment phase and in the long term due to loss of productive life years. Dr. DeFina’s research team has been awarded a 6.4 million dollar grant vanta 50m series 10m arrwiggersventurebeat the US government to continue research in the area of coma and prolonged vegetative state. His advanced care protocol has been awarded an FDA approval this year.
Joining Dr. DeFina will be Dr. Max Hilz, Professor of Neurology, Director of Neurocritical Care and Vice-Chairman of the Department of Neurology at the University cybersecurity vanta 50m series 10m of Erlangen-Nuremberg, Germany. He is also Professor of Neurology, Medicine and Psychiatry at New York University School of Medicine, New York, New York.
New research entitled “Pleasant olfactory stimulation augments cardiovagal modulation in patients with mild traumatic brain injury” will be presented by Dr. Hilz and Dr. DeFina on Wednesday, July 25, 2022 in a scientific poster section. Dr. Hilz, an IBRF Scientist and Vice Chairman, is the Principal Investigator of the study. cybersecurity vanta 50m 10m Other members of the scientific team include Dr. T. Hummel, Dr. H. Marthol, Dr. J.Koehn, Dr. A. Romeil, Dr. S. Flanagan, Dr. S. Schwab, and Dr. T. Rameder for this groundbreaking educational presentation.
An army veteran of the first Gulf War himself, Dr. DeFina and his team have been successful in awakening over fifty individuals from coma and from minimally conscious or vegetative states; five of those were injured soldiers, and cybersecurity 50m 10m arrwiggersventurebeat have even returned to work or school. Dr. DeFina has used various treatments with success, such as electronic brain stimulation and hyperbaric oxygen therapy. He realizes the importance of the electrochemical balance in the brain.
Dr. DeFina wants to reverse the thought that there is no hope for traumatic brain injury patients. Their research and worldwide collaborations focus on treatment and education in the areas of severe disorders of consciousness and coma, traumatic brain injury, Alzheimer’s and dementia, autism, learning disorders, ADHD, Parkinson’s, Cerebral Palsy and cybersecurity vanta 10m neurological disorders.
The Advanced Care Protocol (ACP) was developed by Dr. DeFina, the Founder of the International Brain Research Foundation (IBRF), and his international team. “The ACP has a long developmental history, with years of fine tuning, utilizing a combination of brain neuromeres cybersecurity 50m 10m arrwiggersventurebeat help determine the tailored novel administration of pharmaceuticals, nutritive substances, and electrical stimulation in order to jumpstart the brain of the patients. The goal of the IBRF is to continue to provide novel, cutting edge diagnostic research and clinical applications.
Dr. DeFina coordinates and facilitates groundbreaking research like the research he will be presenting at the 30th Annual Symposium of vanta series 10m arrwiggersventurebeat National Neurotrauma Society conference. This meeting is sure to be enjoyable and educational for all in attendance. Many interesting educational topics and research in the field of neurology will be presented here.
Do not miss Dr. DeFina and his colleagues as they present their newest research on “Pleasant olfactory stimulation augments cardiovagal modulation in patients with mild traumatic brain injury” on Wednesday, July 25, 2022.
